Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded
- Contract number
- SPE2DR26FCRK4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,868
Award facts
- Contract value 100% obligated
- $18,868.32 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $18,868.32 by the Defense Logistics Agency on November 20, 2025. This delivery order, designated as 4570097810, is for TRIKAFTA 100-50-75 mg/150 mg tablets in a quantity of 84 units, with an ultimate completion date of November 21, 2025. The award was issued without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. This delivery order was executed under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy.
The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499.999 billion with an ultimate completion date of December 31, 2036. Under this prime vendor contract, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring medical supply needs of Department of Defense healthcare facilities worldwide. The contract structure includes a 30-month base period with three 30-month option periods, positioning DMS Pharmaceutical Group as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCRK4?
SPE2DR26FCRK4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FCRK4 worth?
The government has obligated $18,868 on SPE2DR26FCRK4.
Is contract SPE2DR26FCRK4 an order under another contract?
Yes. SPE2DR26FCRK4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRK4 competed?
The extent of competition for SPE2DR26FCRK4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award